Nancy Guo
Ludwig Institute for Cancer Research
18 Papers
13 Citations
Nancy Guo is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Medicine & In vivo. The author has an hindex of 4, co-authored 10 publications. Previous affiliations of Nancy Guo include Austin Hospital.
Chat about Author
Papers
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.
Ingrid Burvenich,Ingrid Burvenich,Sagun Parakh,Sagun Parakh,Fook-Thean Lee,Nancy Guo,Zhanqi Liu,Zhanqi Liu,Hui K Gan,Angela Rigopoulos,Angela Rigopoulos,Graeme O'Keefe,Sylvia J. Gong,Yit Wooi Goh,Henri Tochon-Danguy,Fiona Scott,Fiona Scott,Masakatsu Kotsuma,Kenji Hirotani,Giorgio Senaldi,Andrew M. Scott +20 more
TL;DR: In a combined imaging/therapy study, receptor saturation was demonstrated in tumors responding to therapy and indicated that 89Zr-DS-5573a has potential to target B7-H3-expressing tumors in cancer patients.
42
Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a
Ingrid Burvenich,Sagun Parakh,Hui K Gan,Fook-Thean Lee,Nancy Guo,Angela Rigopoulos,Sze Ting Lee,Sylvia J. Gong,Graeme O'Keefe,Henri Tochon-Danguy,Masakatsu Kotsuma,Jun Hasegawa,Giorgio Senaldi,Andrew M. Scott +13 more
TL;DR: Molecular imaging of tumor uptake of DS-8895a allows noninvasive measurement of EphA2 expression in tumors in vivo and determination of receptor saturation, and is suited for human bioimaging trials on the basis of superior imaging characteristics and will inform DS- 8895a dose assessment and patient response evaluation in clinical trials.
25
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers
Hui K Gan,Sagun Parakh,Fook-Thean Lee,Niall C. Tebbutt,Malaka Ameratunga,Sze Ting Lee,Graeme O'Keefe,Sylvia J. Gong,Christine Vanrenen,Jaren Caine,Mary C. Giovannetti,Carmel Murone,Fiona Scott,Nancy Guo,Ingrid Burvenich,Cameron Paine,Mary J. Macri,Masakatsu Kotsuma,Giorgio Senaldi,Ralph Venhaus,Andrew M. Scott +20 more
TL;DR: The biodist distribution data from this study were key in halting further development of DS-8895a, highlighting the importance of biodistribution studies in drug development.
18
Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.
Ingrid Burvenich,Yit Wooi Goh,Nancy Guo,Hui K Gan,Angela Rigopoulos,Diana Cao,Zhanqi Liu,Uwe Ackermann,Uwe Ackermann,Christian Wichmann,Alexander Franklin McDonald,Nhi Huynh,Graeme O'Keefe,Sylvia J. Gong,Fiona Scott,Linghui Li,Wanping Geng,Anup Zutshi,Yan Lan,Andrew M. Scott +19 more
TL;DR: In this article, the authors optimize the 89Zr-radiolabelling of bintrafusp alfa investigational drug product and controls, and perform the in vitro and in vivo characterization of 89 Zr-Df-bintrafusta alfa and 89 Zhr-df-control radioconjugates.
16
In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy.
Ingrid Burvenich,Fook-Thean Lee,Nancy Guo,Hui K Gan,Angela Rigopoulos,Adam C. Parslow,Graeme O'Keefe,Sylvia J. Gong,Henri Tochon-Danguy,Stacey E Rudd,Paul S. Donnelly,Masakatsu Kotsuma,Toshiaki Ohtsuka,Giorgio Senaldi,Andrew M. Scott +14 more
TL;DR: 89Zr-Df-Bz-NCS-DS-8273a is a potential novel PET imaging reagent for human bioimaging trials, and can be used for effective dose assessment and patient response evaluation in clinical trials.
16